Iron deficiency in pulmonary arterial hypertension: perspectives

Marceau Quatredeniers; David Montani; Alain Cohen-Solal; Frédéric Perros

doi:10.1177/20458940211021301

Iron deficiency in pulmonary arterial hypertension: perspectives

Pulm Circ. 2021 Jun 14;11(3):20458940211021301. doi: 10.1177/20458940211021301. eCollection 2021 Jul-Sep.

Authors

Marceau Quatredeniers¹, David Montani¹, Alain Cohen-Solal², Frédéric Perros¹

Affiliations

¹ Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
² Department of Cardiology, Lariboisière Hospital, University of Paris, INSERM UMR_S 942, Paris, France.

Abstract

In left heart failure, iron supplementation (IS) is a first-line treatment option, regardless of anemia. Pulmonary arterial hypertension (PAH), a rare disease leading to right heart failure, is also associated with iron deficiency. While it is a much debated topic, recent evidence demonstrate that restoration of iron stores results in improved right ventricular function and exercise tolerance. Hence, IS may also be considered as an option in the treatment of PAH.

Keywords: hepcidin; iron supplementation; right heart failure.

Publication types

Editorial